Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(1):70-71; doi:10.1093/jnci/dji017
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Saad, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Saad, F.
Related Collections
Right arrowRelated Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

CORRESPONDENCE

RESPONSE: Re: Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Metastatic Hormone-Refractory Prostate Cancer

Fred Saad

Correspondence to: Fred Saad, MD, Director of Urologic Oncology, Professor of Surgery Department of Surgery/Urology, Centre Hospitalier de l'Université de Montréal, Hôpital Notre-Dame, 1560 Rue Sherbrooke East, Montréal, PQ, Canada H2L 4M1 (e-mail: fred.saad@ssss.gouv.qc.ca)

The first 10% of the full text of this article appears below.

Dr. Tanvetyanon raised concerns about the long-term safety of zoledronic acid for the treatment of bone metastases in patients with hormone-refractory prostate cancer. These concerns must be viewed from the perspective of this patient population, in which the median survival is 15 to 18 months. This 24-month randomized, placebo-controlled, double-blind study offers the most stringent and objective assessment of the efficacy and . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Correspondence

Re: Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Metastatic Hormone-Refractory Prostate Cancer
Tawee Tanvetyanon
J Natl Cancer Inst 2005 97: 70. [Extract] [Full Text] [PDF]